申请人:Merck Sharp & Dohme Ltd.
公开号:US06486153B1
公开(公告)日:2002-11-26
A class of tryptamine analogues bearing an optionally substituted phenyl nucleus at the 2-position are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse neurological conditions, including psychotic disorders such as schizophrenia.
一类在2位携带可选择取代的苯环核的色胺类似物是人类5-HT2A受体的选择性拮抗剂,因此在药物代理方面具有用处,特别是在治疗和/或预防不良神经病症方面,包括精神分裂症等精神障碍。